Nouscom Presents New Positive Phase 1/2b data of NOUS-209 at SITC 2025, Supporting Plans to Initiate Registration-Enabling Study for Cancer Interception in Lynch Syndrome Carriers New data from Phase ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback